Neostigmine
Bloxiverz, Neostigmine Methylsulfate (neostigmine) is a small molecule pharmaceutical. Neostigmine was first approved as Bloxiverz on 2013-05-31. It is used to treat drug-induced abnormalities, myasthenia gravis, urinary bladder diseases, and urinary retention in the USA. It is known to target acetylcholinesterase.
Trade Name | Bloxiverz, Neostigmine Methylsulfate |
---|---|
Common Name | Neostigmine |
Indication | drug-induced abnormalities, myasthenia gravis, urinary bladder diseases, urinary retention |
Drug Class | Cholinesterase inhibitors (physostigmine type) |